HIMS
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase… Read more
HIMS (HIMS) - Net Assets
Latest net assets as of December 2025: MX$540.93 Million MXN
Based on the latest financial reports, HIMS (HIMS) has net assets worth MX$540.93 Million MXN as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (MX$2.15 Billion) and total liabilities (MX$1.61 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | MX$540.93 Million |
| % of Total Assets | 25.1% |
| Annual Growth Rate | 12.76% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 16.21 |
HIMS - Net Assets Trend (2021–2025)
This chart illustrates how HIMS's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for HIMS (2021–2025)
The table below shows the annual net assets of HIMS from 2021 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | MX$540.93 Million | +13.47% |
| 2024-12-31 | MX$476.72 Million | +38.57% |
| 2023-12-31 | MX$344.03 Million | +10.36% |
| 2022-12-31 | MX$311.74 Million | -6.84% |
| 2021-12-31 | MX$334.62 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to HIMS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 16517900000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | MX$654.70 Million | 121.03% |
| Total Equity | MX$540.93 Million | 100.00% |
HIMS Competitors by Market Cap
The table below lists competitors of HIMS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Abivax SA American Depositary Shares
NASDAQ:ABVX
|
$4.47 Billion |
|
TPG INC CLASS A DL-001
F:B81
|
$4.47 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
$4.48 Billion |
|
MOL PLC
WAR:MOL
|
$4.48 Billion |
|
Vicor Corporation
NASDAQ:VICR
|
$4.46 Billion |
|
SUMITOMO FORESTRY
F:5F6
|
$4.46 Billion |
|
WASHINGTON H.SOUL PAT.+CO
F:WD3
|
$4.45 Billion |
|
3SBio Inc
F:83B
|
$4.45 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in HIMS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 476,716,000 to 540,928,000, a change of 64,212,000 (13.5%).
- Net income of 128,365,000 contributed positively to equity growth.
- Share repurchases of 89,960,000 reduced equity.
- Other factors increased equity by 25,807,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | MX$128.37 Million | +23.73% |
| Share Repurchases | MX$89.96 Million | -16.63% |
| Other Changes | MX$25.81 Million | +4.77% |
| Total Change | MX$- | 13.47% |
Book Value vs Market Value Analysis
This analysis compares HIMS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 185.69x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 270.51x to 185.69x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | MX$1.63 | MX$442.00 | x |
| 2022-12-31 | MX$1.50 | MX$442.00 | x |
| 2023-12-31 | MX$1.61 | MX$442.00 | x |
| 2024-12-31 | MX$2.16 | MX$442.00 | x |
| 2025-12-31 | MX$2.38 | MX$442.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently HIMS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 23.73%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.47%
- • Asset Turnover: 1.09x
- • Equity Multiplier: 3.98x
- Recent ROE (23.73%) is above the historical average (-1.98%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -32.17% | -39.60% | 0.65x | 1.26x | MX$-141.12 Million |
| 2022 | -21.07% | -12.46% | 1.44x | 1.18x | MX$-96.85 Million |
| 2023 | -6.84% | -2.70% | 1.98x | 1.28x | MX$-57.95 Million |
| 2024 | 26.44% | 8.54% | 2.09x | 1.48x | MX$78.37 Million |
| 2025 | 23.73% | 5.47% | 1.09x | 3.98x | MX$74.27 Million |
Industry Comparison
This section compares HIMS's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
No peer company data available for comparison.